AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.009

+0.000

Volume:3.51M

Turnover:32.28K

Market Cap:59.91M

PE:-1.72

High:0.010

Open:0.009

Low:0.009

Close:0.009

Loading ...

Overview Company News Filings

BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 Million

Alterity Therapeutics - Hy Net Loss After Tax Attributable a$7.2 Mln

THOMSON REUTERS

Alterity Therapeutics Ltd-Proposed Issue of Securities - Ath

THOMSON REUTERS

Alterity Therapeutics Raises AU$40 Million via Placement

MT Newswires Live

Alterity Therapeutics Raises a$40.0 Million in Placement

THOMSON REUTERS

Alterity Therapeutics Ltd - Proceeds to Fund Ongoing Clinical Development for Ath434

THOMSON REUTERS

BUZZ-Australia's Alterity Therapeutics falls on discounted placement

BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSA

Alterity Therapeutics - Alterity Raises a$40M to Advance Ath434 Development in MSA

THOMSON REUTERS

Alterity Therapeutics - Placement Was Conducted at a$0.011 per Share

THOMSON REUTERS

BRIEF-Alterity Therapeutics Seeks Trading Halt

Alterity Therapeutics Ltd - Seeks Trading Halt Pending Announcement on Capital Raising

THOMSON REUTERS

BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market Facility

Alterity Therapeutics Raises About AU$2.1 Million Via US Facility; Shares Soar 17%

MT Newswires Live

Alterity Therapeutics - Raises a$2.13M via Its at-the-Market Facility

THOMSON REUTERS

Alterity Therapeutics Is Maintained at Buy by Maxim Group

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATH.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATH.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.009,"timestamp":1741147861658,"preClose":0.009,"halted":0,"volume":3505440,"delay":0,"changeRate":0,"change":0,"floatShares":4897771134,"shares":6656849000,"eps":-0.00524,"lyrEps":-0.00524,"pbRate":7.69,"amount":32279,"amplitude":0.111111,"volumeRatio":0.168664,"dividePrice":0,"prevYearClose":0.008,"fiveDayClose":0.011,"twentyDayClose":0.012},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":4897771134,"roa":"-78.37%","roe":"-155.77%","lyrEps":-0.00524,"volumeRatio":0.168664,"shares":6656849000,"dividePrice":0,"high":0.01,"amplitude":0.111111,"preClose":0.009,"low":0.009,"week52Low":0.002,"pbRate":"7.69","psRate":"16.09","week52High":0.019,"institutionHeld":0,"latestPrice":0.009,"committee":0.016449,"eps":-0.00524,"divideRate":0,"volume":3505440,"delay":0,"ttmEps":-0.00524,"open":0.009,"prevYearClose":0.008,"prevWeekClose":0.01,"prevMonthClose":0.01,"prevQuarterClose":0.008,"fiveDayClose":0.011,"twentyDayClose":0.012,"sixtyDayClose":0.005},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514336316","title":"BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514336316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514336316?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:11","pubTimestamp":1740705070,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Posts HY Net Loss After Tax Attributable A$7.2 MillionFeb 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX:HY NET LOSS AFTER TAX ATTRIBUTABLE A$7.2 MILLIONFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2514363131","title":"Alterity Therapeutics - Hy Net Loss After Tax Attributable a$7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514363131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514363131?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:10","pubTimestamp":1740705046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2513792579","title":"Alterity Therapeutics Ltd-Proposed Issue of Securities - Ath","url":"https://stock-news.laohu8.com/highlight/detail?id=2513792579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513792579?lang=en_us&edition=fundamental","pubTime":"2025-02-24 13:07","pubTimestamp":1740373635,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUE28YFHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510826250","title":"Alterity Therapeutics Raises AU$40 Million via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510826250","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510826250?lang=en_us&edition=fundamental","pubTime":"2025-02-11 13:05","pubTimestamp":1739250305,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ASX:ATH) is set to raise AU$40 million via a two-tranche placement at AU$0.011 apiece, according to a Monday Australian bourse filing.The first tranche of the placement is to ra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATH.AU","BK7067","LENZ","BK4139"],"gpt_icon":0},{"id":"2510560738","title":"Alterity Therapeutics Raises a$40.0 Million in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510560738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510560738?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:25","pubTimestamp":1739190300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LZFT2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2510395859","title":"Alterity Therapeutics Ltd - Proceeds to Fund Ongoing Clinical Development for Ath434","url":"https://stock-news.laohu8.com/highlight/detail?id=2510395859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510395859?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:25","pubTimestamp":1739190300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA6LZFT2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510705380","title":"BUZZ-Australia's Alterity Therapeutics falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2510705380","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510705380?lang=en_us&edition=fundamental","pubTime":"2025-02-10 10:05","pubTimestamp":1739153104,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Alterity Therapeutics falls on discounted placement** Shares of Australia's Alterity Therapeutics ATH.AX fall as much as 8.3% to A$0.011, on track for a third consecutive session of decline** Stock hits its lowest level since Jan. 31** Biotechnology co raises A$40.0 mln  in a placement at an issue price of A$0.011 per share** Issue price represents a discount of 8.3% to stock's last close** Co says funds will be used primarily to advance development of ATH434, a small molecule drug candidate for Parkinsonian disorders** Stock up 43.8% this year, as of 0159 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL4N3P105B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510074336","title":"BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2510074336","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510074336?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:17","pubTimestamp":1739150223,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Raises A$40M To Advance Ath434 Development In MSAFeb 10  - Alterity Therapeutics Ltd ATH.AX:ALTERITY RAISES A$40M TO ADVANCE ATH434 DEVELOPMENT IN MSAPLACEMENT WAS CONDUCTED AT A$0.011 PER SHAREFurther company coverage: ATH.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3OY2CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510736580","title":"Alterity Therapeutics - Alterity Raises a$40M to Advance Ath434 Development in MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2510736580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510736580?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:23","pubTimestamp":1739143432,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3OY2CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2510307396","title":"Alterity Therapeutics - Placement Was Conducted at a$0.011 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2510307396","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510307396?lang=en_us&edition=fundamental","pubTime":"2025-02-10 07:23","pubTimestamp":1739143432,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250209:nFWN3OY2CT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2509252535","title":"BRIEF-Alterity Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2509252535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509252535?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:55","pubTimestamp":1738792555,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Seeks Trading HaltFeb 6 (Reuters) - Alterity Therapeutics Ltd ATH.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  CAPITAL RAISINGFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW238:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2509252536","title":"Alterity Therapeutics Ltd - Seeks Trading Halt Pending Announcement on  Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2509252536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509252536?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:55","pubTimestamp":1738792530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW238:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2508616891","title":"BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2508616891","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508616891?lang=en_us&edition=fundamental","pubTime":"2025-02-03 09:31","pubTimestamp":1738546295,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Raises A$2.13 Million Via At-The-Market FacilityFeb 3 (Reuters) - Alterity Therapeutics Ltd ATH.AX:RAISES A$2.13M VIA ITS AT-THE-MARKET FACILITYFurther company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OS06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"gpt_icon":0},{"id":"2508157992","title":"Alterity Therapeutics Raises About AU$2.1 Million Via US Facility; Shares Soar 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508157992","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508157992?lang=en_us&edition=fundamental","pubTime":"2025-02-03 08:36","pubTimestamp":1738543005,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  raised about AU$2.1 million capital in the US via an at-the-market facility, according to a Monday Australian filing.The company received the opportunity to raise the capital based on positive topline results from the phase two trial in multiple system atrophy for its ATH434 drug candidate, the filing said.ATH434 is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, it added.The company also expects to receive about AU$5.7 million in rebates from the Australian Taxation Office under the government's Research and Development Tax Incentive scheme.The proceeds will allow it to advance its clinical and regulatory activities.The firm's shares soared almost 17% in early trading on Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XJO.AU","ATH.AU","XKO.AU","BK7067","BK4139","LENZ"],"gpt_icon":0},{"id":"2508513031","title":"Alterity Therapeutics -  Raises a$2.13M via Its at-the-Market Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2508513031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508513031?lang=en_us&edition=fundamental","pubTime":"2025-02-03 06:55","pubTimestamp":1738536920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"gpt_icon":0},{"id":"2507604350","title":"Alterity Therapeutics Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2507604350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507604350?lang=en_us&edition=fundamental","pubTime":"2025-01-31 07:00","pubTimestamp":1738278000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATHE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2025 18:00 ET (23:00 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHE","LENZ","ATH.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":5,"pageCount":1,"totalSize":69}]}}